Basophil Activation Test as a Biomarker for Taxanes Anaphylaxis

Imagem de Miniatura
Arquivos
art_CAMPOS_Basophil_Activation_Test_as_a_Biomarker_for_Taxanes_2022.PDF (926.16 KB)
Citações na Scopus
Tipo de produção
article
Data de publicação
2022
DOI
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
ACHARYA, Shree
LYNCH, Donna-Marie
CASTELLS, Mariana C.
Citação
FRONTIERS IN ALLERGY, v.3, article ID 787749, 9p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IntroductionTaxanes are widely used chemotherapy agents, and their administration, despite premedication, is associated with hypersensitivity reactions (HR) in up to 9% of patients, 1% of which are severe. The mechanisms of these reactions are not fully understood. Finding biomarkers for early diagnosis and better understanding the underlying mechanisms of these reactions are key to defining the best treatment strategy for patients.MethodsThe purpose of this study was to evaluate the effectiveness of the basophil activation test (BAT) to diagnose patients with anaphylactic reactions to taxanes. Patients with anaphylaxis to taxane compounds (n = 15) were assessed through clinical history, skin testing (when possible), and BAT. BAT was performed immediately before rapid drug desensitization or before skin testing using anti-CD123 conjugated (APC-Biolegend), anti-HLADR conjugated (FITC-Biolegend) to gate Basophils and anti-CD63 conjugated (PE-Biolegend), and anti-CD203c conjugated (BV-Biolegend) to assess CD203c and CD63 expression on basophils under taxane stimulation. BAT was also performed in eight healthy volunteers.ResultsBAT was positive for CD203c in eight out of 15 patients and for CD63 in four out of 15 patients and in two out of eight controls. The sensitivity for CD203c was 53%, the specificity was 87%, and the area under the curve was 0.66 (p = 0.19%). For CD63, these rates were 33%, 87%, and 0.6 (p = 0.4). In a subgroup analysis of patients with positive skin tests (11 patients), CD203c was positive in six patients (sensitivity of 54.5% and specificity of 87.5%), and CD63 was positive in five patients (sensitivity of 45% and specificity of 75%).ConclusionsBAT as a diagnostic tool for immediate hypersensitivity reactions to taxanes may be relevant in patients with selected phenotypes and endotypes, especially those with severe reactions or when the diagnosis cannot be established by the skin test. Increased expression of CD203c was more frequent than of CD63 in patients with positive results, and the sensitivity of this biomarker was higher in patient sub-group with positive skin tests, i.e., patients with IgE-mediated endotypes.
Palavras-chave
basophil activation test (BAT), immediate hypersensitivity reaction, taxanes agents, anaphylaxis, chemotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/55998
Referências
  1. Bonamichi-Santos R, 2018, CLIN REV ALLERG IMMU, V54, P375, DOI 10.1007/s12016-016-8556-5
  2. Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029
  3. Bühring HJ, 2001, BLOOD, V97, P3303, DOI 10.1182/blood.V97.10.3303
  4. Bühring HJ, 1999, BLOOD, V94, P2343
  5. Caiado J, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0451-7
  6. Campos L, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0852-8
  7. Castells MC, 2008, CURR PHARM DESIGN, V14, P2892, DOI 10.2174/138161208786369803
  8. Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044
  9. Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P728, DOI 10.1016/j.jaip.2016.11.006
  10. INCA B., 2019, EST 2020 CANC INC BR, P120
  11. Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495
  12. Markman M, 2000, J CLIN ONCOL, V18, P102, DOI 10.1200/JCO.2000.18.1.102
  13. Pagani M, 2022, ALLERGY, V77, P388, DOI 10.1111/all.15113
  14. Pagani M, 2019, J ALLER CL IMM-PRACT, V7, P990, DOI 10.1016/j.jaip.2018.09.018
  15. Picard M, 2016, J ALLERGY CLIN IMMUN, V137, P1154, DOI 10.1016/j.jaci.2015.10.039
  16. Picard M, 2015, CLIN REV ALLERG IMMU, V49, P177, DOI 10.1007/s12016-014-8416-0
  17. Picard M, 2014, J NATL COMPR CANC NE, V12, P389, DOI 10.6004/jnccn.2014.0040
  18. García AP, 2010, J INVEST ALLERG CLIN, V20, P170
  19. Szebeni J, 1998, JNCI-J NATL CANCER I, V90, P300, DOI 10.1093/jnci/90.4.300
  20. Vanhaelen M, 2002, PLANTA MED, V68, P36, DOI 10.1055/s-2002-19865
  21. WEISS RB, 1990, J CLIN ONCOL, V8, P1263, DOI 10.1200/JCO.1990.8.7.1263
  22. Weiszhár Z, 2012, EUR J PHARM SCI, V45, P492, DOI 10.1016/j.ejps.2011.09.016

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - LIM/60